Trials / Completed
CompletedNCT00276315
Assessment of Effectiveness and Safety of Dysport® for the Treatment of Hemifacial Spasm
A Phase III, Multicentre, Randomised, Assessor-blind, Parallel Groups, Reference Drug Controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection of Dysport® for the Treatment of Hemifacial Spasm
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 332 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To compare the effectiveness and safety of Dysport® with the domestic Botulinum Toxin Type A (manufactured by Lanzhou Biologic Product Institute, P.R. China) for the treatment of hemifacial spasm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Botulinum toxin type A |
Timeline
- Start date
- 2005-12-01
- Completion
- 2007-01-01
- First posted
- 2006-01-13
- Last updated
- 2020-04-28
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00276315. Inclusion in this directory is not an endorsement.